As­traZeneca tri­al shows mod­est ben­e­fit in ovar­i­an can­cer, but doc­tors say it's hard to ap­ply find­ings: #AS­CO23

CHICA­GO — Adding As­traZeneca’s Imfinzi and Lyn­parza to the treat­ment reg­i­men for pa­tients with ad­vanced ovar­i­an can­cer and no BR­CA mu­ta­tion ex­tend­ed pro­gres­sion-free sur­vival (PFS) by five months, ac­cord­ing to in­ter­im da­ta re­leased at the AS­CO an­nu­al meet­ing Sat­ur­day morn­ing.

How­ev­er, the de­sign of the Phase III study ob­scures how much Imfinzi is con­tribut­ing to the PFS ex­ten­sion, doc­tors said, mak­ing it dif­fi­cult to ap­ply the find­ings to clin­i­cal prac­tice.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER